What is Utah Medical Products's revenue?

Utah Medical Products (UTMD) generated $37.5M in revenue over the trailing twelve months, down 4.4% year over year.

Is Utah Medical Products profitable?

Utah Medical Products reported $10.8M in net income over the trailing twelve months, a 28.9% net margin.

What are Utah Medical Products's profit margins?

Gross margin is 57.9% and operating margin is 28.8%, with a 28.9% net margin.

What is Utah Medical Products's earnings per share?

Utah Medical Products's diluted EPS over the trailing twelve months is $3.38.

Where does Utah Medical Products's income statement data come from?

Every line is extracted from Utah Medical Products's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Utah Medical Products UTMD Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Total revenue	$37.53M-4.4%	$38.52M-5.8%	$38.63M-12.4%	$38.83M-16.6%	$39.27M-19.9%
Total cost of revenue	$15.79M-3.5%	$16.52M-1.4%	$16.57M-8.7%	$16.57M-13.3%	$16.36M-18.5%
Gross profit	$21.75M-5.1%	$22M-8.9%	$22.06M-14.9%	$22.26M-19.0%	$22.92M-20.9%
Gross margin	57.9%-0.4pp	57.1%-1.9pp	57.1%-1.7pp	57.3%-1.7pp	58.4%-0.7pp
Research and development	$668K-4.8%	$668K-17.9%	$577K-31.2%	$582K-27.7%	$702K+2.8%
Selling, general and administrative	——	——	——	——	——
Selling and marketing	——	$2.05M+7.9%	$2.01M+9.0%	$1.98M+10.2%	$1.94M+11.5%
General and administrative	——	$7.88M+0.6%	$7.87M-8.8%	$7.86M-16.6%	$7.85M-23.2%
Compensation and benefits	$411K+58.7%	$373K+45.7%	$334K+30.5%	$293K+14.5%	$259K+2.0%
Depreciation and amortization	$2.08M+0.9%	$2.13M+3.0%	$2.11M-12.7%	$2.09M-40.4%	$2.06M-55.3%
Provision for credit losses	——	——	——	——	——
Goodwill impairment	——	——	——	——	——
Other operating expenses	810,900,000.3%+45,000,000%	777,700,000.3%-38,000,000%	777,700,000.2%-38,000,000%	724,300,000.2%-184,500,000%	765,900,000.2%-192,800,000%
Total operating expenses	——	——	——	——	——
Operating income	$10.81M-15.9%	$11.4M-16.1%	$11.89M-18.6%	$12.62M-17.1%	$12.86M-20.7%
Operating margin	28.8%-3.9pp	29.6%-3.6pp	30.8%-2.4pp	32.5%-0.2pp	32.8%-0.3pp
Interest expense	$0—	$0—	$0—	$0—	$0—
Other income (expense), net	-$208K+45.8%	-$120K+31.0%	-$655K—	-$517K—	-$384K—
Income before income taxes	$13.43M-53.8%	$14.11M-53.0%	$27.81M-16.4%	$28.68M-15.4%	$29.05M-16.6%
Income tax expense	$2.58M-49.5%	$2.82M-45.1%	$5.21M-8.1%	$5.15M-12.7%	$5.12M-16.3%
Net income	$10.85M-16.3%	$11.29M-18.7%	$11.62M-23.8%	$12.55M-19.7%	$12.96M-20.9%
Net margin	28.9%-4.1pp	29.3%-4.6pp	30.1%-4.5pp	32.3%-1.2pp	33%-0.4pp
Diluted earnings per share	$3.38-10.8%	$3.48-12.1%	$3.54-17.3%	$3.75-13.4%	$3.79-15.8%
Basic earnings per share	$3.38-10.6%	$3.48-11.9%	$3.54-17.1%	$3.74-13.6%	$3.78-16.2%
Weighted-average shares, diluted	12.9M-6.8%	13M-8.0%	13.3M-7.0%	13.5M-6.2%	13.8M-4.9%
Weighted-average shares, basic	12.9M-6.8%	13M-8.0%	13.3M-7.0%	13.5M-6.0%	13.8M-4.7%
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity	——	——	——	——	——
Amortization of capitalized software and acquired intangible assets	$2.08M+0.9%	$2.13M+3.0%	$2.11M-12.7%	$2.09M-40.4%	$2.06M-55.3%
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation	$4.08M+139%	$2.78M+128%	-$4.19M-1,822%	-$7.04M-253%	-$10.48M-181%
Company Sales In Europe	——	$7.93M-8.9%	$8.12M-7.3%	$8.32M-5.6%	$8.51M-4.0%
Company Sales In The United States	——	$22.76M-4.7%	$23.04M-9.7%	$23.32M-14.1%	$23.6M-18.0%
Company Sales Other	——	$7.83M-5.9%	$7.95M-11.3%	$8.08M-15.9%	$8.2M-20.0%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$12.12M-7.2%	$13.78M+9.1%	$11.77M-32.2%	$14.51M-5.1%	$13.06M-21.2%
Federal	——	$2.65M+17.6%	$2.55M+12.6%	$2.45M+7.6%	$2.35M+2.7%
Foreign	——	$319K-38.1%	$368K-48.9%	$417K-55.0%	$466K-58.8%
Current State And Local Tax Expense Benefit	——	$474K-6.0%	$481.5K-1.3%	$489K+3.7%	$496.5K+9.1%
Federal	——	-$44K-140%	-$5.5K-116%	$33K+183%	$71.5K+162%
Deferred Foreign Income Tax Expense Benefit	——	-$559K-8.3%	-$548.25K-13.3%	-$537.5K-19.0%	-$526.75K-25.6%
Deferred taxes	-$589K—	-$641K—	——	——	——
State	——	-$10K-115%	$8.75K-76.7%	$27.5K+175%	$46.25K+364%
Defined contribution plan costs	——	$211K+1.0%	$210.5K+3.8%	$210K+6.9%	$209.5K+10.1%
Depreciation	$837K+8.1%	$826K+13.2%	$814K+18.3%	$808K+26.3%	$774K+24.0%
Dividends, Common Stock, Cash	$3.94M-4.1%	$3.96M-5.6%	$3.98M-6.5%	$4.05M-5.8%	$4.11M-4.7%
Effect of exchange rate changes on cash, cash equivalents and restricted cash	——	——	——	——	——
Income taxes at U.S. statutory rate of 21%	——	——	——	——	——
Other	——	$0—	$0—	——	——
State income taxes – net of federal income tax benefit	——	——	——	——	——
Effective Income Tax Rate Reconciliation Tax Credits Research	——	——	——	——	——
Income tax benefit realized from option exercises	——	$0-100%	$5K-72.2%	$10K-37.5%	$15K+7.1%
Foreign Income Taxes Ireland	——	$602K—	$1.25M—	——	——
Foreign Income Taxes Other Foreign	——	-$3K—	$116.75K—	——	——
Foreign Income Taxes Other Foreign Percent	——	——	——	——	——
Foreign Income Taxes Precent Ireland	——	——	——	——	——
Foreign Income Taxes Precent United Kingdom	——	——	——	——	——
Foreign Income Taxes United Kingdom	——	-$839K—	-$1.55M—	——	——
Foreign Currency Translation and Other Adjustments	——	——	——	——	——
Goodwill impairment losses	——	——	——	——	——
Income Loss From Continuing Operations Before Income Taxes Domestic	——	$11.8M—	$22.15M—	——	——
Income Loss From Continuing Operations Before Income Taxes Foreign	——	$2.31M—	$5.23M—	——	——
Federal taxes	——	——	——	——	——
Foreign	——	——	——	——	——
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount	——	$2.48M—	$4.65M—	——	——
Income Tax Reconciliation Non Deductible Expense Tax Exempt Income	——	-$165K—	-$324.75K—	——	——
Income Tax Reconciliation Non Deductible Expense Tax Exempt Income Percent	——	——	——	——	——
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount	——	$30K—	$53.5K—	——	——
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount	——	-$43K—	-$214.25K—	——	——
Income Tax Reconciliation Section965Tax	——	$353K—	——	——	——
Income Tax Reconciliation Section965Tax Percent	——	——	——	——	——
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount	——	$428K—	$825K—	——	——
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount	——	$15K—	$29.25K—	——	——
Income taxes paid	$3.99M-12.9%	$4M-13.7%	$3.78M-25.2%	$4.17M-17.7%	$4.58M-4.7%
Accounts payable	——	——	——	——	-$86K—
Increase (Decrease) in Accounts Receivable and Other Operating Assets	——	——	——	——	——
Accrued liabilities	——	——	——	-$2.25M-85.5%	-$1.69M-38.4%
Increase (Decrease) in Deferred Income Taxes	——	-$659K-83.6%	-$584K-32.0%	-$509K+3.2%	-$434K+28.8%
Increase (Decrease) in Inventories	-$90K+84.8%	-$1.2M-104%	-$1.09M—	-$1.05M—	-$591K—
Increase (Decrease) in Other Receivables	——	$5K+109%	-$9.75K+75.9%	-$24.5K+9.3%	-$39.25K-191%
Increase (Decrease) in Prepaid Expense and Other Assets	$120K+514%	$54K+68.8%	$34K+143%	-$68K+21.8%	-$29K—
Interest Paid, Excluding Capitalized Interest, Operating Activity	——	——	——	——	——
Lessee Operating Lease For Parking Lot Adjustment To Lease Payments Required Every Five Years Based On Change In CPI	——	——	——	——	——
Litigation Expense	——	$1.36M-36.7%	$1.55M-23.2%	$1.75M-8.0%	$1.94M+9.2%
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	-$9.22M+61.7%	-$12.34M+48.2%	-$18.11M-5.5%	-$21.39M-61.1%	-$24.09M-239%
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	-$317K+20.2%	-$371K-78.4%	-$271K+6.2%	-$333K+13.7%	-$397K+32.8%
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	$13.34M-4.9%	$14.69M-0.9%	$14.15M-17.8%	$14.13M-23.6%	$14.02M-32.1%
Operating lease right-of-use assets amortization expense	$59K+20.4%	$56K+9.8%	$54K+3.8%	$51K-3.8%	$49K-9.3%
Foreign currency translation gains (losses)	$1.27M+1,184%	$2.49M+299%	$152K-92.8%	$1.96M+683%	$99K-50.7%
Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax	$0—	$0—	$0—	$0—	$0—
Other Interest And Dividend Income	——	$2.81M-16.6%	$2.95M-10.2%	$3.09M-3.6%	$3.23M+3.5%
Other income, net (Note 6)	-$208K+45.8%	-$120K+31.0%	-$655K—	-$517K—	-$384K—
Payments for Repurchase of Common Stock	$5.26M-73.9%	$8.36M-58.2%	$14.07M+6.1%	$17.28M+84.0%	$20.2M+576%
Payments of Dividends	$3.96M-5.6%	$3.98M-6.5%	$4.04M-5.8%	$4.11M-4.7%	$4.19M-2.6%
Payments to Acquire Property, Plant, and Equipment	$317K-19.1%	$371K+61.3%	$271K-12.9%	$333K-18.4%	$392K-36.6%
Net additions (releases) charged to costs and expenses	——	——	——	——	——
Stock-based compensation	$411K+58.7%	$373K+45.7%	$334K+30.5%	$293K+14.5%	$259K+2.0%
Expected volatility	——	——	——	——	——
Weighted-average grant date fair value of stock options (in dollars per share)	——	——	——	——	——
Risk-free rate	——	——	——	——	——
Options granted (in shares)	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period	——	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments	——	$0.33+3.2%	$0.32+2.9%	$0.32+2.6%	$0.32+2.3%
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised	——	——	——	——	——
Intrinsic value of stock options exercised	——	$0-100%	$19.25K-70.6%	$38.5K-28.7%	$57.75K+35.9%
Stock Option Plan Expense	$412K+59.1%	$374K+46.1%	$335K+30.9%	$293K+14.5%	$259K+2.0%
Value of shares repurchased	-$5.26M+49.0%	-$8.36M+17.2%	-$4.2M+68.3%	-$7.41M+21.1%	-$10.33M-245%
EBIT	$10.81M-15.9%	$11.4M-16.1%	$11.89M-18.6%	$12.62M-17.1%	$12.86M-20.7%
EBITDA	$13.73M-12.5%	$14.35M-12.4%	$14.81M-16.4%	$15.52M-19.9%	$15.7M-26.8%
EBITDA	$13.73M-12.5%	$14.35M-12.4%	$14.81M-16.4%	$15.52M-19.9%	$15.7M-26.8%
EBITDA margin	36.6%-3.4pp	37.3%-2.8pp	38.3%-1.8pp	40%-1.6pp	40%-3.8pp
EBIT	$10.81M-15.9%	$11.4M-16.1%	$11.89M-18.6%	$12.62M-17.1%	$12.86M-20.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Utah Medical Products.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Utah Medical Products's revenue?: Utah Medical Products (UTMD) generated $37.5M in revenue over the trailing twelve months, down 4.4% year over year.
Is Utah Medical Products profitable?: Utah Medical Products reported $10.8M in net income over the trailing twelve months, a 28.9% net margin.
What are Utah Medical Products's profit margins?: Gross margin is 57.9% and operating margin is 28.8%, with a 28.9% net margin.
What is Utah Medical Products's earnings per share?: Utah Medical Products's diluted EPS over the trailing twelve months is $3.38.
Where does Utah Medical Products's income statement data come from?: Every line is extracted from Utah Medical Products's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.